Chanan-Khan, Asher <br/><br/>
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.  [electronic resource] 

 -  The Lancet. Oncology  Feb 2016 
 - 200-211 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1474-5488 
<br/><br/><label>Standard No.: </label>10.1016/S1470-2045(15)00465-9  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenine--analogs & derivatives<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Anemia--chemically induced<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Atrial Fibrillation--chemically induced<br/>Bendamustine Hydrochloride--administration & dosage<br/>Disease Progression<br/>Disease-Free Survival<br/>Double-Blind Method<br/>Female<br/>Hemorrhage--chemically induced<br/>Humans<br/>Intention to Treat Analysis<br/>Leukemia, Lymphocytic, Chronic, B-Cell--drug therapy<br/>Male<br/>Middle Aged<br/>Nausea--chemically induced<br/>Neutropenia--chemically induced<br/>Piperidines<br/>Pyrazoles--administration & dosage<br/>Pyrimidines--administration & dosage<br/>Retreatment<br/>Rituximab--administration & dosage<br/>Thrombocytopenia--chemically induced